# US 2017/0281623 A1 · Solid forms of an epidermal growth factor receptor kinase inhibitor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0281623 A1
- Document ID: US20170281623A1
- Status: Published application
- Kind: A1
- Application number: 15/401,663
- Filed: 2017-01-09
- Published: 2017-10-05
- Earliest claimed: 2012-03-15
- Assignees: Celgene CAR LLC
- Applicants: Celgene CAR LLC
- Inventors: Mei Lai
- Web page: https://patentgrep.com/patent/US20170281623A1

## CPC

- A61K 31/506: not condensed and containing further heterocyclic rings
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 239/48: Two nitrogen atoms
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present invention provides a solid form and composites thereof, which are useful as an inhibitor of EGFR kinases and which exhibit desirable characteristics for the same.

## Claims

### Claim at position 1

1-33. (canceled)

### Claim 34

A composition comprising a solid form of Compound 1:
wherein the solid form of Compound 1 is selected from the group consisting of Form A, Form B, Form C, Form D, Form E, Form F, Form G, Form H, and Form I; and
wherein the composition is substantially free of impurities.

### Claim 35 (depends on 34)

The composition of claim 34, wherein the composition comprises at least about 90% by weight of the solid form of Compound 1.

### Claim 36 (depends on 35)

The composition of claim 35, wherein the composition comprises at least about 95% by weight of the solid form of Compound 1.

### Claim 37 (depends on 36)

The composition of claim 36, wherein the composition comprises at least about 97% by weight of the solid form of Compound 1.

### Claim 38 (depends on 37)

The composition of claim 37, wherein the composition comprises at least about 98% by weight of the solid form of Compound 1.

### Claim 39 (depends on 38)

The composition of claim 38, wherein the composition comprises at least about 99% by weight of the solid form of Compound 1.

### Claim 40 (depends on 39)

The composition of claim 39, wherein the composition comprises at least about 99.5% by weight of the solid form of Compound 1.

### Claim 41 (depends on 40)

The composition of claim 40, wherein the composition comprises at least about 99.8% by weight of the solid form of Compound 1.

### Claim 42 (depends on 34)

The composition of claim 34, wherein the composition contains no more than 5.0 area percent HPLC of total organic impurities relative to the total area of an HPLC chromatogram of the solid form of Compound 1.

### Claim 43 (depends on 42)

The composition of claim 42, wherein the composition contains no more than 3.0 area percent HPLC of total organic impurities relative to the total area of an HPLC chromatogram of the solid form of Compound 1.

### Claim 44 (depends on 43)

The composition of claim 43, wherein the composition contains no more than 1.5 area percent HPLC of total organic impurities relative to the total area of an HPLC chromatogram of the solid form of Compound 1.

### Claim 45 (depends on 44)

The composition of claim 44, wherein the composition contains no more than 1.0 area percent HPLC of total organic impurities relative to the total area of an HPLC chromatogram of the solid form of Compound 1.

### Claim 46 (depends on 45)

The composition of claim 45, wherein the composition contains no more than 0.6 area percent HPLC of total organic impurities relative to the total area of an HPLC chromatogram of the solid form of Compound 1.

### Claim 47 (depends on 46)

The composition of claim 46, wherein the composition contains no more than 0.5 area percent HPLC of total organic impurities relative to the total area of an HPLC chromatogram of the solid form of Compound 1.

### Claim 48

A composition comprising Compound 1:
wherein Compound 1 is a crystalline solid form substantially free of an amorphous form of Compound 1.

### Claim 49 (depends on 48)

The composition of claim 48, wherein Compound 1 is at least 90% crystalline.

### Claim 50 (depends on 49)

The composition of claim 49, wherein Compound 1 is at least 95% crystalline.

### Claim 51 (depends on 50)

The composition of claim 50, wherein Compound 1 is at least 97% crystalline.

### Claim 52 (depends on 51)

The composition of claim 51, wherein Compound 1 is at least 98% crystalline.

### Claim 53 (depends on 52)

The composition of claim 52, wherein Compound 1 is at least 99% crystalline.
